Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452681 | 0.80 | SLC7A5 (0.41) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL28738543 | 0.75 | SLC7A5 (0.50) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL23120097 | 0.75 | SLC7A5 (0.50) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL23120674 | 0.75 | MAPT (0.51) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL6843793 | 0.75 | MAPT (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1162358 | 0.74 | MAPT (0.47) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1996403 | 0.72 | MAPT (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1520299 | 0.72 | MAPT (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1520373 | 0.72 | ALDH1A1 (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1079740 | 0.72 | MAPT (0.68) | MAPTALDH1A1RECQLSLC7A5ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201947-A1 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-08-18 | — | — | US | claimed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | claimed |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMA (US) | 2025-09-18 | — | — | US | disclosed |
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4524147-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524236-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524148-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524237-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-2510361-A2 | DETECTION OF OXIDIZED POLYPEPTIDES | Purdue Research Foundation (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8143224-B2 | Oxidant resistant apolipoprotein A-1 and mimetic peptides | THE CLEVELAND CLINIC FOUNDATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110201947-A1 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011072197-A2 | DETECTION OF OXIDIZED POLYPEPTIDES | PURDUE RESEARCH FOUNDATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2212351-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | The Cleveland Clinic Foundation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090149390-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | THE CLEVELAND CLINIC FOUNDATION | 2009-06-11 | — | — | US | disclosed |
| WO-2009055538-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | MAPT 2868/4885ALDH1A1 4194/4885RECQL 3264/4885 |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | MAPT 2868/4885ALDH1A1 4194/4885RECQL 3264/4885 |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | MAPT 2868/4885ALDH1A1 4194/4885RECQL 3264/4885 |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | MAPT 2868/4885ALDH1A1 4194/4885RECQL 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.